조현병 환자에서 QT 간격 지연과 흡연의 연관성

키워드

참고문헌 (43)

1. Osby U, "Mortality and causes of death in schizophrenia in Stockholm county, Sweden", Schizophr Res, 45, pp.21~28 (2000)
2. Saha S, "A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?", Arch Gen Psychiatry, 64, pp.1123~1131 (2007)
3. Laursen TM, "Life expectancy and cardiovascular mortality in persons with schizophrenia", Curr Opin Psychiatry, 25, pp.83~88 (2012)
4. Wildgust HJ, "The paradox of premature mortality in schizophrenia: new research questions", J Psychopharmacol, 24, pp.9~15 (2010)
5. Wildgust HJ, "Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?", J Psychopharmacol, 24, pp.37~50 (2010)
6. Bushe CJ, "Mortality in schizophrenia: a measurable clinical endpoint", J Psychopharmacol, 24, pp.17~25 (2010)
7. Josephson M, "Implantable defibrillators and sudden cardiac death", Circulation, 109, pp.2685~2691 (2004)
8. Charlotte van Noord, "Drug- and non-drug-associated QT interval prolongation", Br J Clin Pharmacol, 70, pp.16~23 (2010)
9. A Algra, "QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest", Circulation, 83, pp.1888~1894 (1991)
10. Glassman AH, "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death", Am J Psychiatry, 158, pp.1774~1782 (2001)
11. Algra A, "QT interval variables from 24 hour electrocardiography and the two year risk of sudden death", Br Heart J, 70, pp.43~48 (1993)
12. Karjalainen J, "QT interval as a cardiac risk factor in a middle aged population", Heart, 77, pp.543~548 (1997)
13. Makkar RR, "Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs", JAMA, 270, pp.2590~2597 (1993)
14. Wang Q, "Genetics, molecular mechanisms and management of long QT syndrome", Ann Med, 30, pp.58~65 (1998)
15. Cubeddu LX, "QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs", Am J Ther, 10, pp.452~457 (2003)
16. Roden DM., "Drug-induced prolongation of the QT interval", N Engl J Med, 350, pp.1013~1022 (2004)
17. Reilly JG, "QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients", Lancet, 355, pp.1048~1052 (2000)
18. Lasser KE, "Timing of new black box warnings and withdrawals for prescription medications", JAMA, 287, pp.2215~2220 (2002)
19. Thompson C., "The use of high-dose antipsychotic medication", Br J Psychiatry, 164, pp.448~458 (1994)
20. Ammar R, "Evaluation of electrocardiographic and hemodynamic effects of caffeine with acute dosing in healthy volunteers", Pharmacotherapy, 21, pp.437~442 (2001)
21. Dilaveris P, "The effects of cigarette smoking on the heterogeneity of ventricular repolarization", Am Heart J, 142, pp.833~837 (2001)
22. Fauchier L, "Association between heart rate-corrected QT interval and coronary risk factors in 2,894 healthy subjects(the DESIR Study). Data from an Epidemiological Study on the Insulin Resistance syndrome", Am J Cardiol, 86, pp.557~559 (2000)
23. Phutane VH, "Cardiovascular risk in a first-episode psychosis sample: a ‘critical period’ for prevention?", Schizophr Res, 127, pp.257~261 (2011)
24. Newman SC, "Mortality in a cohort of patients with schizophrenia: a record linkage study", Can J Psychiatry, 36, pp.239~245 (1991)
25. Ray WA, "Antipsychotics and the risk of sudden cardiac death", Arch Gen Psychiatry, 58, pp.1161~1167 (2001)
26. Kelly C, "Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale", Scotland. Am J Psychiatry, 156, pp.1751~1757 (1999)
27. Association AP, "Diagnostic and Statistical Manual of Mental Disorder" (1994), American Psychiatric Association
28. Ramos-Rios R, "QTc interval in a sample of long-term schizophrenia inpatients", Schizophr Res, 116, pp.35~43 (2010)
29. Rey MJ, "Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics", Int Clin Psychopharmacol, 4, pp.95~104 (1989)
30. Kahn RS, "Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial", Lancet, 371, pp.1085~1097 (2008)
31. Girola A, "QT dispersion in uncomplicated human obesity", Obes Res, 9, pp.71~77 (2001)
32. Arslan E, "Effect of uncomplicated obesity on QT interval in young men", Pol Arch Med Wewn, 120, pp.209~213 (2010)
33. Papaioannou A, "Effects of weight loss on QT interval in morbidly obese patients", Obes Surg, 13, pp.869~873 (2003)
34. Gupta AK, "Effect of weight loss on QT dispersion in obesity", Indian Heart J, 54, pp.399~403 (2002)
35. Mackin P, "QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study", J Clin Psychiatry, 66, pp.1386~1391 (2005)
36. Rettenbacher MA, "QTc variability in schizophrenia patients treated with antipsychotics and healthy controls", J Clin Psychopharmacol, 25, pp.206~210 (2005)
37. Novotny T, "Monitoring of QT interval in patients treated with psychotropic drugs", Int J Cardiol, 117, pp.329~332 (2007)
38. Fraguas Herraez D, "Factors related to the length of the corrected QT interval in patients treated with antipsychotics", Med Clin(Barc), 130, pp.446~449 (2008)
39. Sala M, "Caverzasi E, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy", Ann Gen Psychiatry, 4, pp.1~ (2005)
40. Elming H, "The importance of the QT interval: a review of the literature", Acta Psychiatr Scand, 107, pp.96~101 (2003)
41. Singh K., "Effect of smoking on QT interval, QT dispersion and rate pressure product", Indian Heart J, 56, pp.140~142 (2004)
42. Ziegler D, "Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general population", Exp Clin Endocrinol Diabetes, 114, pp.153~159 (2006)
43. Mangoni AA, "Impact of age on QT interval and QT dispersion in healthy subjects: a regression analysis", Age Ageing, 32, pp.326~331 (2003)

관련 논문AI추천